WALTHAM, Mass. , Aug. 29, 2024 /PRNewswire/ -- Q32 Bio Inc.
(Nasdaq: QTTB ) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference Date: Thursday, September 5, 2024 Location: New York, NY 2024 Cantor Fitzgerald Global Healthcare Conference Date: Tuesday, September 17, 2024 Presentation Time: 3:40 p.m. E.
T. Location: New York, NY Stifel 2024 Virtual Immunology and Inflammation Summit Date: Wednesday, September 18, 2024 Presentation Time: 11:30 a.m.
E.T. Location: Virtual A webcast of the Cantor and Stifel presentations will be available on the Events and Presentations page of Q32 Bio's website at www.
q32bio.com . Archived replays will be available for 30 days following the event.
About Q32 Bio Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune .